StockNews.com Lowers Actinium Pharmaceuticals (NYSE:ATNM) to Sell

StockNews.com cut shares of Actinium Pharmaceuticals (NYSE:ATNM) from a hold rating to a sell rating in a report issued on Wednesday morning.

A number of other research firms have also issued reports on ATNM. B. Riley lowered Actinium Pharmaceuticals from a buy rating to a neutral rating and decreased their target price for the company from $16.00 to $2.00 in a report on Wednesday, August 7th. HC Wainwright decreased their target price on Actinium Pharmaceuticals from $50.00 to $4.00 and set a buy rating for the company in a report on Tuesday, August 6th. Finally, Maxim Group decreased their target price on Actinium Pharmaceuticals from $30.00 to $5.00 and set a buy rating for the company in a report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Actinium Pharmaceuticals presently has a consensus rating of Moderate Buy and a consensus target price of $11.40.

Actinium Pharmaceuticals Stock Performance

ATNM opened at $1.80 on Wednesday. Actinium Pharmaceuticals has a 52 week low of $1.33 and a 52 week high of $10.24. The stock’s fifty day moving average price is $3.69. The stock has a market capitalization of $53.61 million, a price-to-earnings ratio of -1.05 and a beta of 0.14.

Actinium Pharmaceuticals (NYSE:ATNM) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.02. Research analysts expect that Actinium Pharmaceuticals will post -1.38 earnings per share for the current year.

Institutional Trading of Actinium Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Sanders Morris Harris LLC purchased a new stake in Actinium Pharmaceuticals during the 1st quarter worth about $78,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter worth about $92,000. Renaissance Technologies LLC acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter worth about $142,000. Rhumbline Advisers increased its position in shares of Actinium Pharmaceuticals by 23.4% during the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter worth about $356,000. 27.50% of the stock is owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.